Exact Sciences Corporation

EXASintermediary

Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology. Its Cologuard test has become the leading non-invasive colorectal cancer screening tool, and its multi-cancer early detection test aims to transform cancer diagnosis.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($2.8B)

靜態數據（加載即時財務…）

Screening (Cologuard) (55%)

Precision Oncology (Oncotype DX) (35%)

Other / Pipeline (10%)

業務部門構成與主要客戶

產品詳情

Cologuard (Colorectal Cancer)45%

Non-invasive stool DNA test for colorectal cancer screening

Oncotype DX (Breast Cancer)30%

Genomic test predicting breast cancer recurrence risk

Multi-Cancer Early Detection (MCED)10%

Blood-based test detecting multiple cancer types from a single draw

供應鏈關係

合作夥伴

Pfizer Inc.

Cancer screening combined with pharma treatment

影響: Low — co-marketing exploration

Eli Lilly and Company

Companion diagnostics for oncology drugs

影響: Low — diagnostic partnerships

Regeneron Pharmaceuticals

Genomic profiling for antibody therapies

影響: Low

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Exact Sciences Corporation 的 AI 供應鏈分析。

企業資訊

總部

Madison, Wisconsin, USA

成立時間

1995

員工人數

7,200+

官網

exactsciences.com

行業概況 — 제약 / 바이오

行業新聞